Surrozen Inc (SRZN)

Over the past six months, Surrozen's stock price has increased significantly. Positive analyst coverage, including initiations with "Buy" or "Overweight" recommendations and raised price targets, impacted the stock. In March 2026, Surrozen received a milestone payment from Boehringer Ingelheim. Earnings reports for Q1 2026, Q4 2025, Q3 2025, and Q2 2025 showed varying financial results. CEO Craig Parker sold shares of the company's stock. The company has emphasized its shift toward ophthalmology and the advancement of SZN-8141 and SZN-8143.

Surrozen, Inc.'s products and services do not exhibit traditional demand seasonality. The demand for its drug candidates is primarily driven by the progression of clinical trials, regulatory approvals, and the prevalence of the specific diseases they aim to treat, which are not subject to seasonal fluctuations.

Surrozen, Inc. is a clinical-stage biotechnology company focused on discovering and developing drug candidates that modulate the Wnt pathway for tissue repair and regeneration. The company operates in the Health Technology sector, specifically in Biotechnology and Drug Discovery. Surrozen's primary focus is on severe ophthalmic and retinal diseases, utilizing its antibody-engineering platform to create multifunctional biologics. Its pipeline includes SZN-8141 for DME and wet AMD, combining Fzd4 agonism and VEGF antagonism; SZN-8143, also targeting DME, wet AMD, and UME, combining Fzd4 agonism, VEGF antagonism, and IL-6 antagonism; SZN-043, a tissue-specific R-spondin mimetic for severe liver disease; and SZN-1326, a bi-specific antibody for intestinal disorders.

Surrozen, Inc. is headquartered in South San Francisco, California, and is incorporated in Delaware. It has a subsidiary named Surrozen Netherlands, B.V., located in Amsterdam.

Surrozen's brand reputation over the past year appears positive, particularly within the investment community. The company has received an average recommendation of "Moderate Buy" from ratings firms. Progress in its ophthalmology pipeline, positive preclinical data, strategic collaborations, and analyst endorsements have contributed to this positive reputation. While earnings reports have sometimes led to modest negative stock reactions, the overall sentiment remains positive.

Surrozen, Inc. has a diverse ownership structure. Institutional shareholders hold a significant portion, while Surrozen insiders also hold a notable percentage, and retail investors hold a smaller portion. Major institutional and individual owners include Life Sciences Consonance, The Column Group, LLC, and several other investment firms.